Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Minnelide™ in Patients With Advanced GI Tumors

This study has been completed.
Information provided by (Responsible Party):
Minneamrita Therapeutics LLC Identifier:
First received: August 19, 2013
Last updated: March 2, 2017
Last verified: March 2017
The primary objective of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™ and to establish the dose of Minnelide™ recommended for future phase 2 protocol

Condition Intervention Phase
Advanced Gastrointestinal Tumors
Drug: Minnelide™ 001
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.

Resource links provided by NLM:

Further study details as provided by Minneamrita Therapeutics LLC:

Primary Outcome Measures:
  • To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™ [ Time Frame: 24 months ]
    The MTD will be determined using a 3 + 3 design and will continue until 2 patients at any dose level experience a DLT. A DLT will be defined as Grade 4 neutropenia lasting ≥ 5 days or Grade 3 or 4 neutropenia with fever and/or infection;Grade 4 thrombocytopenia (or Grade 3 with bleeding);Grade 3 or 4 treatment-related non-hematological toxicity (Grade 3 nausea, vomiting or diarrhea that last > 72 hours despite maximal treatment constitutes a DLT, insufficient treatment will not constitute an exception to the DLT criteria, as this would constitute inadequate conduct of the study); Dosing delay greater than 2 weeks due to treatment-emergent AEs or related severe laboratory abnormalities.

  • To establish the dose of Minnelide™ recommended for future phase 2 protocol [ Time Frame: 24 months ]
    Once the MTD has been determined this will be the dose going forward in phase 2 studies

Secondary Outcome Measures:
  • To determine the pharmacokinetics of Minnelide™ [ Time Frame: 24 months ]

    Plasma concentration data will be used to determine the following PK parameters:

    • AUC Area under the concentration curve
    • Cmax Maximum plasma concentration
    • Tmax Time to maximum plasma concentration
    • t1/2 Terminal phase half life
    • CL/F Total body clearance
    • Vd/F Apparent volume of distribution

  • To observe patients for any evidence of antitumor activity of Minnelide™ per RECIST criteria [ Time Frame: 24 months ]
    Objective measurements of tumor size will be recorded from PET, CT scan and other measures.

  • To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans. [ Time Frame: 24 months ]

    As part of exploratory PD, the following assessments will be performed:

    • Biomarkers including CA19-9 (or CA125, CEA if non-secretors for pancreas cancer), CEA and CA125 as applicable, any tumor marker appropriate to the given cancer or that is known to be elevated in a given patient will be evaluated according the Investigator's discretion, prior to every Cycle.
    • Serum HSP70 levels
    • PET Scans
    • Evaluation of CT scans using Choi criteria

Enrollment: 45
Study Start Date: August 2013
Study Completion Date: December 2016
Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Minnelide™ 001
A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
Drug: Minnelide™ 001
Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
Other Name: Minnelide

Detailed Description:

This is a Phase 1, open label, multicenter, dose-escalation study of safety, pharmacokinetics, and pharmacodynamics of Minnelide™

Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Dose escalation will follow a modified Fibonacci design.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Inclusion Criteria:

  1. Histologically or cytologically confirmed gastrointestinal (GI) carcinoma, which has progressed on standard therapies (surgery, radiotherapy, endocrine therapy, chemotherapy), for which effective therapy is not available or for which patients are not a candidate for or intolerant of such therapies.
  2. Have one or more metastatic tumors measurable on CT scan or locally advanced measurable disease that has clearly progressed after prior treatment per RECIST criteria.
  3. Male and female patients at least 18 years of age
  4. Laboratory data as specified:

    • Hematology: ANC >1500 cells/mm3, platelet count > 150,000 cells/mm3 and Hemoglobin > 9 g/dL
    • Hepatic: Direct bilirubin ≤1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 X ULN. For patients with known liver metastases or liver neoplasms, then ALT or AST ≤ 5.0 X ULN is allowed
    • Renal: serum creatinine WNL or calculated creatinine clearance ≥ 50 mL/min/1.73m2 for patients with creatinine levels above institutional normal
    • Urinalysis: No clinically significant abnormalities
    • Coagulation: INR within normal limits, PTT within normal limits
  5. Estimated life expectancy of at least 3 months
  6. Karnofsky Performance ≥ 70%
  7. A negative serum pregnancy test (if female)
  8. For men and women of child-producing potential - willingness to employ appropriate contraceptive methods (including abstinence) during the study.
  9. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.

Exclusion Criteria:

  1. Women who are pregnant or nursing. NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  2. New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.
  3. Baseline QTc exceeding 450 msec (470 msec for females) using the Bazetts formula and/or patients receiving class 1A or class III antiarrythmic agents.
  4. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
  5. Treatment with radiotherapy, chemotherapy or investigational therapy within 1 month (or 5 half lifes for cytotoxics) prior to study entry (6 weeks for nitrosoureas or Mitomycin C).
  6. Known HIV, Hepatitis A, B or Hepatitis C infection
  7. Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.
  8. Participation in concurrent study of an investigational agent or device.
  9. Unwillingness or inability to comply with procedures required in this protocol.
  10. Any other condition including but not limited to major co-morbidities, which in the opinion of the investigator would render the patient ineligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01927965

United States, Arizona
Virginia G. Piper Cancer Center at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
United States, Minnesota
University of Minnesota Masonic Cancer Clinic
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Minneamrita Therapeutics LLC
Study Director: Mohana Velagapudi, MD Minneamrita Therapeutics LLC
Study Director: Linda Vocila, BSN TD2
  More Information

Additional Information:

Responsible Party: Minneamrita Therapeutics LLC Identifier: NCT01927965     History of Changes
Other Study ID Numbers: Minnelide™ 001
Study First Received: August 19, 2013
Last Updated: March 2, 2017

Keywords provided by Minneamrita Therapeutics LLC:
gastrointestinal tract
GI tract
advanced gastrointestinal tumors
gastrointestinal tumors
GI tumors

Additional relevant MeSH terms:
Digestive System Neoplasms
Gastrointestinal Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases processed this record on April 27, 2017